NFATc1 is the target for calcineurin inhibitors used for treating nephrotic syndrome, serum IFN-γ is increased in nephrotic syndrome, and JAK/STAT signaling is important in FSGS and in recurrence of FSGS following transplantation (11, 12, 68, 69). This evidence concerns the gene NFATC1 and focal segmental glomerulosclerosis.